Lv11
48 积分 2021-04-22 加入
Mechanisms of resistance to antibody–drug conjugates in cancers
1个月前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
1个月前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
1个月前
已完结
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
1个月前
已完结
Top advances of the year: Small cell lung cancer
4个月前
已完结
Small cell lung cancer: Subtypes and therapeutic implications
4个月前
已完结
B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy
4个月前
已完结
Integrated transcriptomics and proteomics data analysis identifies CDH17 as a key cell surface target in colorectal cancer
5个月前
已完结
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma
6个月前
已完结
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
6个月前
已完结
皖公网安备34019202002308
